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Abstract
The establishment and maintenance of Epstein-Barr Virus (EBV) latent infection requires distinct viral gene expression
programs. These gene expression programs, termed latency types, are determined largely by promoter selection, and
controlled through the interplay between cell-type specific transcription factors, chromatin structure, and epigenetic
modifications. We used a genome-wide chromatin-immunoprecipitation (ChIP) assay to identify epigenetic modifications
that correlate with different latency types. We found that the chromatin insulator protein CTCF binds at several key
regulatory nodes in the EBV genome and may compartmentalize epigenetic modifications across the viral genome. Highly
enriched CTCF binding sites were identified at the promoter regions upstream of Cp, Wp, EBERs, and Qp. Since Qp is
essential for long-term maintenance of viral genomes in type I latency and epithelial cell infections, we focused on the role
of CTCF in regulating Qp. Purified CTCF bound ,40 bp upstream of the EBNA1 binding sites located at +10 bp relative to
the transcriptional initiation site at Qp. Mutagenesis of the CTCF binding site in EBV bacmids resulted in a decrease in the
recovery of stable hygromycin-resistant episomes in 293 cells. EBV lacking the Qp CTCF site showed a decrease in Qp
transcription initiation and a corresponding increase in Cp and Fp promoter utilization at 8 weeks post-transfection.
However, by 16 weeks post-transfection, bacmids lacking CTCF sites had no detectable Qp transcription and showed high
levels of histone H3 K9 methylation and CpG DNA methylation at the Qp initiation site. These findings provide direct genetic
evidence that CTCF functions as a chromatin insulator that prevents the promiscuous transcription of surrounding genes
and blocks the epigenetic silencing of an essential promoter, Qp, during EBV latent infection.
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Introduction
Epstein-Barr Virus (EBV) is a human gamma herpesvirus
that establishes latent infection in more than 90% of the adult
population world-wide [1,2]. The ,170 kb genome encodes ,90
viral genes but only a few of these are expressed during latent
infection. The latent infection is a cofactor in several human
malignancies and may play an essential causative role in the
endemic forms of Burkitt’s lymphoma (BL) and nasopharyngeal
carcinoma (NPC), as well as diffuse B-cell lymphomas in HIV-
AIDS and iatrogenic immunosuppressed individuals [3]. Remark-
ably, the viral gene expression patterns vary in each tumor type
suggesting that EBV can establish multiple forms of latency [4].
These different gene expression programs have been referred to as
latency types and may also correlate with the changes in host-cell
differentiation state and tissue origin [4,5]. Changes in EBV
latency type may also be important for evasion of host-immune
recognition [6].
EBV latency gene expression programs have been categorized
into four different types based primarily on the differential
expression of the EBNA and LMP gene transcripts [4]. Type 0
latency is defined as the absence of expression of any viral genes,
and is thought to exist in quiescent memory B-cells [5,7]. Type I
latency is characterized by the expression of the EBNA1 gene only,
and is observed in proliferating memory B-cells in normal hosts,
and found predominantly in Burkitt lymphoma tissue and derived
cell lines [8,9,10]. Type II latency is characterized by the
expression of EBNA1 and LMP2 expression, with some variable
expression of LMP1. This pattern of gene expression is observed in
epithelial cell derived tumors including NPC and gastric
carcinomas [11,12,13]. Type III latency is characterized by the
expression of EBNA-1, -2, -3A, -3B, -3C,-LP, LMP1, LMP2. This
more permissive gene expression program is observed upon
primary infection of naı ¨ve B-cells and is associated with B-cell
proliferation and immortalization [14]. Type III latency is
observed in immortalized B-cells in culture and diffuse B-cell
lymphomas in immunosuppressed individuals. The natural history
of EBV infection suggests that type III latency progresses to type I
latency during B-cell maturation, and that viral lytic occurs in
terminally differentiating plasma B-cells [5,15].
Latency type gene expression is regulated largely through
differential promoter utilization [16,17,18,19,20]. The promoters
for type III infection are activated upon primary infection by B-cell
specific factors [21]. Initial transcription from Wp promoter allows
the expression of EBNA2, which functions as a transcriptional
activator or the Cp promoter which drives expression of EBNA-
LP, EBNA-2, EBNA-3A, -3B, -3C and EBNA1 [22,23,24,25].
EBNA2 also activates LMP1 and LMP2 transcription to maintain
type III gene expression [25]. Type II and Type I gene expression
arise through mechanisms that are not completely understood,
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promoter by DNA methylation and histone deacetylation
[26,27,28,29,30,31,32,33]. EBNA1 expression is required for the
replication and maintenance of the viral latent genome
[34,35,36,37]. EBNA1 mRNA expression is maintained in type
III latency by Cp promoter utilization and mRNA processing,
while in type I latency EBNA1 expression is driven largely through
the Q promoter (Qp) [17,31,38,39,40]. EBNA1 protein binds to
two sites located at the +10–+57 position relative to the Qp
transcription initiation site and restrict its usage in type III cells
where EBNA1 proteins levels are elevated [41,42]. Thus, EBNA1
can autoregulate its own expression levels through promoter
selection, and help to coordinate the switch between latency types.
The epigenetic control of EBV promoter utilization and latency
type is evident in the differential pattern of DNA methylation
between latency types, and by the ability of DNA methylation
inhibitors to stimulate type III gene transcription from type I
latently infected cells [26,43]. It is also apparent that histone
acetylation occurs at the Cp promoter during type III latency
where they are transcribed, but not in type I latency where Cp
promoter is silenced [44]. However, little else is known about the
epigenetic controls the determine promoter utilization and gene
expression during the different latency types. LMP1 and Cp
activation depend on the enhancer functions of EBNA2 and
EBNA1. EBNA1 binds to the EBV origin of plasmid (OriP)
replication and is essential for both viral replication and plasmid
maintenance, as well as for transcriptional enhancement of
EBNA2 and LMP1 [45,46,47]. The mechanism through which
EBNA1 activates Cp and LMP1 from OriP, which is located over
2 kb from each promoter is not clear. It is also not known whether
EBNA1 binding at Qp may also regulate transcription of type III
promoters.
Cellular factors that regulate communication between promot-
ers and enhancers, have also been implicated in the organization
of chromatin structure [48,49,50,51]. The chromatin insulator
protein CTCF has been implicated in segregating active from
inactive chromatin domains, as well as in mediating long-distance
interactions between transcriptional regulatory regions [52,53]. At
least one CTCF site has been mapped to a region between OriP
and Cp, and its binding was found to correlate with the inhibition
of Cp transcription in type I latency [54,55]. Other CTCF sites in
EBV chromosome are known to exist, but their function has not
been explored in detail [54]. In this work, we use a genome-wide
ChIP assays to explore the epigenetic landscape of the EBV
genome in type I and type III infected cells. We found that CTCF
binding sites are positioned in key regulatory locations throughout
the viral genome. We investigate in detail the function of a high
affinity CTCF site positioned immediately upstream of the
EBNA1 binding sites in Qp. We find that CTCF binding is
required to maintain the transcriptional activity and prevent the
epigenetic silencing of Qp in proliferating cells.
Results
Epigenetic differences between type I and type III
genomes
An EBV genome-wide real-time PCR array was used to
compare the patterns of several epigenetic marks between type I
and type III latent virus genomes using the chromatin immuno-
precipitation (ChIP) assay (Fig. 1). For these experiments we used a
384-well array that covers the entire EBV genome at a density of
,400 bp between primer sets. In a previous study, we used a
similar approach to analyze the first 60 kb of the EBV genome for
various histone modifications and protein factor binding sites [54].
In the present study, we compared a type I latently infected Burkitt
lymphoma cell line, Mutu I, with a lymphoblastoid cell line
derived from Mutu I viral DNA (Mutu-LCL), ensuring that these
two cell types were isogenic with respect to EBV genomes. We
compared the pattern of CTCF binding sites to those of histone
H3me3K9 (H3mK9) and H3me2K4 (H3mK4) modifications and
also that of cytosine methylation (mCpG) using methyl DNA
immunoprecipitation (MeDIP). Several patterns were noteable.
Peaks of histone H3mK9 and H3mK4 were complementary and
non-overlapping. Major peaks of H3mK4 were detected at the
regions surrounding the RNA polymerase III transcribed EBERS
and the Bam A microRNA cluster in both cell types. H3mK4
peaks regions surrounding the LMP1 promoter and Cp promoter
were elevated in type III relative to type I cells. H3mK9
methylation was elevated over the Cp and W repeats in type I
latency, but not type III, correlating with transcription repression
in type I. CTCF binding sites were located at multiple positions,
with only a few differences in type I and type III. CTCF sites
tended to exist between clusters of H3mK4 and H3mK9, as can be
seen at a newly discovered peak at the region 39 of the W repeats.
All the CTCF binding sites found in our assay are listed in Table
S1. mCpG patterns were also different between type I and III
latency. High levels of mCpG were detected across the Cp and
LMP2 regions in type I, but not in type III, correlating with
transcription silencing of Cp/Wp in type I cells. Interestingly,
CTCF sites tended to demarcate boundaries of mCpG, which also
correlated well with H3mK9 in both cell types.
A more detailed examination of the regions surrounding the
major latency promoter elements reveals other features relevant to
epigenetic regulation (Fig. 2). While most CTCF sites are bound
similarly in each cell type, the CTCF site upstream of the EBERS
was significantly reduced in Mutu I cells (Fig. 2A). Interestingly,
this region is enriched in mCpG in MutuI, relative to type III cells
(Fig. 2B). One possible explanation for the loss of CTCF binding at
this region in type I cells is that enriched DNA methylation
replaces and blocks CTCF binding. In contrast, this same region is
elevated in H3mK9 in type III latency, where CTCF occupies a 39
boundary upstream of the EBERS (Fig. 2D and 2J). Another
striking feature is the elevated H3mK4 across the EBNA2
transcript and BHRF1 miRNA cluster in type III latency, but
not in type I (Fig. 2C). This correlates well with the difference in
RNA polymerase II transcription across this region in these two
cell types. The CTCF site at this position just 39 of W repeats
provides a 59 border for the high H3mK4 in type III latency
Author Summary
Epstein-Barr Virus (EBV) establishes a latent infection that is
associated with several lymphoid and epithelial cell
malignancies. The latent virus persists as a circular
minichromosome in the nucleus of infected cells. Epige-
netic modifications of the viral DNA and chromatin are
known to control viral gene expression and genome
stability, but the nature and mechanisms of these
epigenetic marks are not known. Here, we use viral
genome-wide analysis to characterize patterns of DNA and
histone methylation, and how these are organized by the
chromatin boundary factor CTCF. Mutation of one such
CTCF site at the EBV Q promoter results in aberrant
accumulation of DNA CpG methylation and histone H3 K9
trimethylation, and the consequent silencing of Qp
transcription. We conclude that CTCF chromatin insulator
function is required for the epigenetic programming and
stable maintenance of latent viral infection.
Insulator Function of CTCF at Qp
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mCpG (Fig. 2G) in type I latency.
CTCF binds consistently at Qp in both cell types (Fig. 2A). In
type I cells, the Qp CTCF site separates a 39 H3mK4 peak from a
59 region enriched in H3mK9 and mCpG (Fig. 2E–G). In type III
cells, the CTCF site appears to spare Qp from surrounding regions
of elevated mCpG and H3 mK9 (Fig. 2H and J). The region is also
reduced in H3mK4, corresponding to a reduction in EBNA1
binding and transcription from Qp (Fig. 2I). These marks are
largely consistent with known transcription properties of Qp in
which it is active in type I, and repressed in type III (Figure S1).
Mapping the CTCF site at Qp
To identify the specific sequence element bound by CTCF near
Qp, we first examined the region for candidate CTCF binding sites
using a prediction algorithm (http://insulatordb.uthsc.edu). At least
two candidate CTCF sites were identified at positions 43739 and
50082 (Fig. 3A). These sites were synthesized as DNA oligonucleotide
probes and tested by EMSA for binding to purified recombinant
CTCF protein (Fig. 3B and C). We found that CTCF bound
efficiently to the 50082 binding site, but not to the 49739 sequence or
to a control oligonucleotide (from EBV 49901) that lacked any
candidate CTCF binding site (Fig. 3C). The precise nucleotide
binding site of CTCF was mapped by DNase I footprinting using the
entire Qp control region as a probe and purified recombinant CTCF
(Fig. 3D). Wefound that CTCFprotected a ,20 bp regions between
50082–50102. In the same DNase footprinting reaction we included
recombinant EBNA1 protein. EBNA1 bound to two sites in Qp
covering EBV nucleotides 50142 to 50189.
The DNase I footprinting assays demonstrate that CTCF and
EBNA1 can bind simultaneously to Qp, and that potential
interactions between these proteins may regulate Qp. However,
detailed biochemical analysis of these interactions were limited by
the different salt sensitivities of the purified proteins in the DNA
binding assays (Fig. 3D). The physiological significance of this
differential salt sensitivity is not clear.
Generation of an EBV Bacmid with CTCF mutations at Qp
To investigate the functional significance of CTCF binding at
Qp in cell-based assays, we engineered a substitution mutation in
the CTCF binding site at Qp in EBV bacmids using recombineer-
ing with GALK gene insertion and gene replacement [56] (http://
recombineering.ncifcrf.gov) (Fig. 4A). GALK insertion, CTCF
substitution mutation (DCTCF), and Wild-type (Wt) rescue
mutants in EBV bacmids were validated by restriction enzyme
digestion (Fig. 4B), PCR across the junctions (Fig. 4C) and
sequencing of the insertions (data not shown). Bacmid DNA for
DCTCF and Wt rescue control was introduced into 293 cells and
stable transformants were selected for hygromycin and GFP
expression. After 8 weeks of selection, stable cell pools were
Figure 1. EBV genome-wide analysis of histone and DNA methylation patterns in different latency types. ChIP assays were performed
with Mutu I (A–D), or Mutu-LCL (E–H) using antibodies for histone H3me2K4 (A and E), H3me3K9 (B and F), CTCF (C and G), or methyl cytosine (MeDIP)
(D–H). ChIP DNA was assayed by real-time PCR using a genome wide array of 384 primers spaced ,400 bp across the EBV genome. Approximate EBV
genome positions are indicated in the schematic below each column of graphs. Graphs represent an average of three independent experiments.
Standard deviation was less than 10 percent of the mean for all data points.
doi:10.1371/journal.ppat.1001048.g001
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disrupted CTCF binding in living cells (Fig. 4D). As expected,
CTCF failed to bind to Qp in the DCTCF mutant (Fig. 4D, top
panel). We also found that EBNA1 binding to Qp was reduced in
the DCTCF mutant (Fig. 4D, lower panel), suggesting that CTCF
facilitates EBNA1 binding at Qp in living cells. Stable cell pools
were also assayed at 8 weeks for their relative expression GFP,
EBNA1, CTCF and PCNA (Fig. 4E). We found no apparent
differences in the expression of these proteins after 8 weeks of
selection in 293 cell pools.
CTCF binding site at Qp is required for stable
maintenance of EBV episomes in 293 cells
While early passage cell pools showed little difference in GFP
and EBNA1 expression between DCTCF and Wt rescue genomes,
Figure 2. Analysis of epigenetic patterns in the EBV latency control region. A–D) EBV genome-wide ChIP data from figure 1 was reanalyzed
at EBV positions 1–60 kb as direct comparison between Mutu I (blue) and Mutu-LCL (red) for CTCF (panel A), methyl cytosine (panel B), H3me2K4
(panel C), H3me3K9 (panel D). E–G) Mutu I cells compared for CTCF (blue) vs methyl cytosine (red); CTCF (blue) vs H3me2K4 (green); CTCF (blue) vs
H3me3K9 (yellow). H–J) Mutu-LCL-III cells compared for CTCF (blue) vs methyl cytosine (red); CTCF (blue) vs H3me2K4 (green); CTCF (blue) vs
H3me3K9 (yellow).
doi:10.1371/journal.ppat.1001048.g002
Insulator Function of CTCF at Qp
PLoS Pathogens | www.plospathogens.org 4 August 2010 | Volume 6 | Issue 8 | e1001048we observed a marked loss of GFP expression in the DCTCF
relative to Wt rescue genomes after longer passages in culture
(Fig. 5A and B). At 4 and 8 weeks after transfection, DCTCF and
Wt rescue had nearly identical percentage of GFP positive cells. In
contrast, at 16 weeks DCTCF pools were ,9% positive, while Wt
rescue was ,72% GFP positive, as measured by FACS (Fig. 5B).
EBV DNA copy number per cell was determined by real time
PCR for 293 cell pools at 8 and 16 weeks (Fig. 5C). We found that
DCTCF cell pools had ,50% less EBV DNA per cell than Wt
rescue containing pools as measured at 8 and 16 weeks. Isolation
of EBV episomes by Hirt lysis revealed that DCTCF cell pools had
,3 fold lower DNA than WT rescue at 8 weeks, and both pools
were reduced at 16 weeks, indicating that DCTCF episomes are
lost at a greater rate than Wt episomes (Fig. 5D). These data
suggest that the Qp CTCF binding site is important for the stable
maintenance of EBV episomes in selected 293 cell pools.
DCTCF genomes have altered transcription and
promoter usage
The loss of GFP expression and episome stability in 293 cell
pools could be due to a deregulation of viral gene expression.
Others have shown that EBV establishes a restricted pattern of
latency gene expression in 293 cells, resembling a type I program
with stable Qp utilization for EBNA1 expression [57]. To assess
viral gene expression patterns in transfected 293 cells, we first
assay mRNA expression of EBNA1, EBNA2, EBNA3A, and
EBNA3C in 293 cell pools after 4, 8, and 16 weeks of selection
(Fig. 6). RNA expression was measured by quantitative RT-PCR
and normalized to bacmid expression of GFP mRNA. At 4 weeks,
EBNA1 and EBNA2 mRNA levels were expressed at lower levels
in DCTCF compared to Wt rescue cell pools (Fig. 6C, top panel).
At 8 weeks, EBNA1 levels were similar, while EBNA2, EBNA3A,
and EBNA3C levels were higher in DCTCF relative to Wt rescue
cell pools (Fig. 6C, middle panel). By 16 weeks, EBNA1 mRNA
levels were maintained in the Wt rescue, but almost undetectable
in DCTCF cell pools (Fig. 6C, lower panel). EBNA2, EBNA3A,
and EBNA3C were expressed at very low levels in both Wt rescue
and DCTCF cell pools at these later passages in culture. These
observations are consistent with a previous study showing that
EBV initially expresses EBNA2, but eventually adopts an EBNA1
only, type I latency in 293 cells [57].
To better understand the failure of DCTCF bacmids to sustain
EBNA1 mRNA expression, we investigated the promoter utiliz-
ation at 4, 8, and 16 weeks after transfection (Fig. 6D). EBNA1
mRNA has been shown to initiate from Wp/Cp in most type III
latency, from Qp in most type I latency, and from Fp during lytic
cycle gene expression (Fig. 6A and B). We assayed the utilization
of Wp/Cp, Qp, and Fp using quantitative RT-PCR with primers
specific for each promoter (Table S2). At 4 weeks, we found that
Wp/Cp was utilized at similar levels in Wt rescue and DCTCF
Figure 3. Identification of a CTCF binding site upstream of Qp. A) Schematic of CTCF and EBNA1 binding site organization at Qp, and the
sequence of candidate CTCF binding sties (BS) 1 and 2. B) Coomassie stain of purified recombinant CTCF and EBNA1 proteins derived from
baculovirus expression system. C) EMSA analysis of purified CTCF (10–100 ng) binding to DNA probes for EBV regions 49730–49768 (BS1), 49901–
49939, or 50072–50113 (BS2). D) DNase I footprinting assay of purified CTCF protein (30–300 ng) in the absence (-) or addition (+) of 30 ng purified
EBNA1, in buffer containing 150 mM (left panel) or 75 mM (right panel) NaCl.
doi:10.1371/journal.ppat.1001048.g003
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DNA for EBV Wt, GAL K, Wt rescue, and DCTCF was analyzed by Sal I restriction digest and 0.7% agarose gel electrophoresis. DNA was visualized by
ethidium bromide staining. C) PCR amplification of the region encompassing Qp for EBV Wt, GAL K, Wt rescue and DCTCF. D and E) ChIP assay of Wt
rescue, or DCTCF bacmids in stable 293 cell pools after 8 weeks of hygromycin selection with antibody for CTCF (top panel), or EBNA1 (lower panel).
CTCF ChIP was analyzed at Qp or a region 25 kb to Qp. EBNA1 ChIP was analyzed at Qp, or at OriLyt control region. E) Western blot analysis of CTCF,
GFP, EBNA1, and PCNA protein levels for Wt rescue or DCTCF 293 cell pools.
doi:10.1371/journal.ppat.1001048.g004
Figure 5. CTCF binding site at Qp is required for stable maintenance of EBV episome in 293 cells. A) Photomicrographs of GFP
fluorescence of EBV bacmid Wt rescue or DCTCF in 293 cell pools after 4, 8 and 16 weeks post-transfection. B) EBV episome maintenance in Wt rescue
or DCTCF 293 cell pools was assayed by FACS analysis as the percentage of GFP positive cells at the indicated weeks. Bars represent the average of
three independent experiments. C) EBV genome copy number was assayed by real time PCR analysis in Wt rescue or DCTCF 293 cell pools at the
indicated weeks. Bars represent the average of three independent experiments. D) Episomal viral DNA from Wt rescue or DCTCF 293 cell pools was
isolated at the indicated weeks by Hirt extraction and assayed by quantitative real time PCR using the viral DNA from Raji cells as reference (DDCt
method). Bars represent the rate of episome lost of three independent experiments. All error bars indicate the standard deviation from the mean.
doi:10.1371/journal.ppat.1001048.g005
Insulator Function of CTCF at Qp
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was utilized at relatively high levels in Wt rescue, but nearly
undetectable in DCTCF. Interestingly, Fp utilization was
detected in DCTCF, but undetectable in Wt rescue. At 8 weeks,
Wt rescue containing cells utilized Qp predominantly, while
DCTCF cells utilized all three promoters, with Fp dominating
(Fig. 6D, middle panel). By 16 weeks, Wt rescue genomes utilized
Qp exclusively, while DCTCF genomes utilized Fp exclusively,
although , 10 fold less than Fp utilization at 8 weeks (Fig. 6D,
lower panel). Since Fp is typically associated with lytic gene
activity, we tested whether DCTCF containing cells were
expressing the lytic immediate early gene BZLF1 (Fig. S3 and
Fig. 6E). BZLF1 expression was undetectable at all time points
tested for Wt or DCTCF 293 cell pools, as measured by
quantitative RT-PCR (Fig.S3) or by conventional PCR (Fig. 6E).
These findings suggest that latency promoter utilization is
deregulated in DCTCF genomes.
To better understand the DCTCF defects in viral gene
expression, we assayed viral mRNA using exon specific PCR for
transcripts (Table S3), initiating at Qp (QUK), Cp (C1C2W1W2),
Wp (W0W1W2), or within the lytic transcripts of BFLF1 [58]
(Fig. 6E). In addition, we measured the UK intron junction for
EBNA1, which is expressed in type I and type III cells. We also
measure BZLF1 expression as an indicator of lytic cycle gene
expression. As a control we assayed the expression levels of cellular
GAPDH. RNA was isolated from pools after 8 weeks in culture.
We found that QUK was expressed at slightly higher levels in Wt
rescue relative to DCTCF cell pools (Fig. 6E, top panel).
C1C2W1W2,W 0W1W2 and FQUK transcripts were elevated in
DCTCF relative to Wt rescue, consistent with RT-PCR data
showing elevated levels of Wp/Cp and Fp utilization in bacmid
lacking the CTCF binding site. UK transcripts were similar in
DCTCF and Wt rescue, consistent with observations from
quantitative RT-PCR (Fig. 6C) showing that EBNA1 mRNA
Figure 6. RNA expression and promoter utilization in Qp mutated bacmids. A) Schematic representation of the EBV latency genes and
promoters. Promoters are indicated by arrows. The position of the six EBNAs ORFs are indicated. B) Schematic representation of different EBNA1
transcripts. Exons present at 59 end of EBNA1 mRNA are indicated in red. C) Quantitative RT-PCR was used to measure the abundance of EBNA2,
EBNA3A and EBNA3C mRNA relative to bacmid GFP for Wt rescue or DCTCF bacmids in 293 cell pools at 4, 8, and 16 weeks after transfection, as
indicated. D) Same as in C, except EBNA1-transcripts initiating from either Cp/Wp, Qp, or Fp were measured relative to GFP in Wt rescue or DCTCF
bacmids in 293 cell pools at 4, 8, and 16 weeks after transfection. E) RT-PCR was measured for Wt rescue or DCTCF bacmids in 293 cell pools at 8
weeks post-transfection, as well as for type I (Mutu I) or type III (Mutu-LCL) controls. RNA was analyzed for the junction specific transcripts QUK (Qp
initiation), C1C2W1W2 (Cp initiation), W0W1W2 (Wp initiation), BFLF1 (lytic gene adjacent to Qp), UK (EBNA1 mRNA in both type I and type III), and
control cellular GAPDH.
doi:10.1371/journal.ppat.1001048.g006
Insulator Function of CTCF at Qp
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detected in either bacmid 293 cell pool, indicating that lytic gene
activation or DNA replication was not indirectly responsible for
these differences in gene expression. These exon-specific PCR
studies further substantiate the real-time PCR data, and support
the conclusion that CTCF mutations in Qp deregulate the latency
type transcription pattern and promoter utilization.
CTCF binding site is required for the maintenance of
epigenetic patterns at Qp
CTCF has been implicated in several functions, including
chromatin insulation and boundary functions. To determine if the
disruption of CTCF site at Qp altered the normal pattern of
epigenetic marks surrounding Qp, we performed MeDIP and
ChIP assays with a set of primers that probe the regions 21000,
2500, +1, and +800 relative to the Qp initiation site (Fig. 7A–C).
At 8 weeks post-transfection, MeDIP revealed that mCpG was
enriched at 21000 and 2500 position in Wt rescue, but
undetectable in DCTCF genomes (Fig. 7A, top panel). At 16
weeks post-transfection, mCpG was elevated at 21000 in WT
rescue, but not at +1o r+800, consistent with high levels of
transcription initiating at Qp in these cell pools (Fig. 6). In
contrast, mCpG was elevated at +1 position in DCTCF genomes,
consistent with the lack of Qp transcription initiation at 16 weeks
in DCTCF cells (Fig. 6). To examine potential changes in
euchromatic or heterochromatic histone modifications surround-
ing Qp, we focused on H3mK4 or H3mK9, respectively. At 8
weeks post-transfection, we found high levels of H3mK4 at the +1
and +800 positions in both Wt rescue and DCTCF genomes
(Fig. 7B, top panel). At 16 weeks, H3mK4 was elevated primarily
in Wt rescue (Fig. 7B, lower panel), consistent with persistent
transcription from Qp in these cells (Fig. 6). The heterochromatic
mark for histone H3mK9 was more revealing since it showed
elevated levels upstream of Qp (21000 and 2500) in Wt rescue
genomes at 8 weeks (Fig. 7C, top panel), and low levels in DCTCF
where Fp is active. At 16 weeks, H3mK9 was highly enriched at
+1 site of Qp in DCTCF genomes (Fig. 7C, lower panel),
consistent with the transcription inactivity of Qp in these cells at
Figure 7. Changes in epigenetic patterns in Qp mutated bacmids. A) The epigenetic pattern of Qp region in Wt rescue and DCTCF bacmids in
293 cell pools was analyzed by MeDIP assay (A), H3me2K4 (B) and H3me3K9 (C) ChIp assay at 8 weeks (top panel) or 16 weeks (lower panel) after
transfection. A schematic representation of Qp region is shown. D) Model of CTCF function in the chromatin organization at EBV Q promoter. CTCF is
positioned as a barrier to the 59 encroachment of H3me3K9 and mCpG in Wt rescue 293 cells (top panel). In DCTCF 293 cells, H3me2K4 is enriched
throughout Qp and Fp at 8 weeks (lower panel, left), but is converted to H3me3K9 and mCpG at later times (16 weeks) (lower panel, right), indicating
that CTCF is required to prevent this epigenetic drift at Qp.
doi:10.1371/journal.ppat.1001048.g007
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and Wp was also examined (Fig. S5). We found that Cp and Wp
were hypermethylated and enriched on H3mK9 both at 8 and 16
weeks in Wt rescue, consistent with a previous study demonstrat-
ing that Cp and Wp undergo transcription silencing in 293 cells
[57]. In DCTCF genomes Cp and Wp are hypomethylated and
enriched on H3mK4 at 8 weeks, consistent with transcription
initiation. However, by 16 weeks, Cp and Wp show elevated
mCpG and H3mK9, consistent with the extinction of transcription
initiation from these promoters at later passages. Thus, Cp and
Wp undergo similar epigenetic silencing with Wt and DCTCF
genomes, but Qp is protected from epigenetic silencing only in
genomes were the CTCF site is intact (Fig. 7D).
Discussion
Stable gene expression programs, like those associated with cell-
type differentiation, correlate with heritable epigenetic changes to
the cellular chromosome. The meta-stable gene expression
programs associated with Epstein-Barr virus latency types have
also been shown to correlate with epigenetic changes in the viral
genome. The most consistently observed epigenetic difference
between type I and type III latency is the DNA methylation of the
Cp and LMP1 promoter regions [26,43,59]. We and others have
also explored histone modification patterns at the major latency
control regions for EBV, and observed distinct patterns between
cell lines carrying EBV genomes with either type I and type III
latency [44,54,60]. In this work, we extended this approach to
examine the pattern of histone H3 K4 and K9 methylation, DNA
methylation, and CTCF binding across the complete EBV
genome in cells carrying stable type I or type III EBV latent
infections (Figs 1 and 2, Figs. S1 and S2). We found that CTCF
binding sites were located at or near regulatory regions, and
commonly marked boundaries between euchromatic and hetero-
chromatic marks (Fig. 2). The heterochromatic mark was typically
H3mK9 in type III latency (e.g. EBV regions 2–6 kb in Fig. 2D),
and mCpG, especially in type I latency (e.g. EBV regions 2–6 kb
in Fig. 2B). This may reflect the natural history of epigenetic
silencing where a partially repressive histone modification, like
H3mK9 in type III, may eventually evolve into the more stable
silencing modification associated with DNA methylation in type I.
In some cases, the emergence of extensive CpG methylation
correlates with the loss of CTCF binding (e.g. EBV region ,6k b
in Fig. 2E and 2H). CTCF binding is known to be sensitive to
CpG methylation [61]. These observations suggest that CTCF
plays a key role in organizing epigenetic marks along the EBV
genome, and that CTCF binding and epigenetic patterns change
in different latency types.
To directly test the function of CTCF and other sequence
specific binding factors in maintaining EBV latency type gene
expression programs, we focused on the EBV Q promoter. We
found that CTCF bound to Qp, and we used DNase I footprinting
to map this binding site to a ,20 bp region located ,40 bp
upstream of the EBNA1 binding sites (Fig. 3). In type I cells,
CTCF appeared to separate a 39 enrichment of H3mK4 that
overlaps the Q transcription initiation site, from a 59 enrichment of
CpG methylation, that covers the neighboring lytic BFLF1 gene
(Fig. 2E–G, Fig. S1). In type III cells, CTCF appears to spare the
Qp transcription initiation site from surrounding H3 K9
methylation (Fig. 2I). To directly test the function of CTCF
binding at Qp, we used recombineering methods to engineer a
mutation that disrupts CTCF binding in EBV bacmids (Fig. 4).
Disruption of CTCF binding site at Qp caused a loss of stable GFP
expression and loss of bacmid episomes after multiple cell divisions
(Fig. 5). CTCF site disruption also caused an increase in Fp
promoter utilization, with no other evidence of lytic gene
activation (Fig. 6C–E). Consistent with changes in gene expression,
CTCF site disruption allowed for the formation of mCpG and
H3mK9 methylation at the Qp initiation site (Fig. 7). These
finding strongly suggest that CTCF contributes to the establish-
ment and maintenance of an epigenetic pattern at Qp which is
required for consistent expression of EBNA1 and episomal
persistence in 293 cells pools. These findings also suggest that
CTCF provides a barrier function that normally prevents Fp
activation (upstream) and Qp silencing (downstream) during latent
infection (Fig. 7D).
CTCF has been implicated in several gene regulatory and
chromatin organizing activities [52,53]. At the H19/Igf2 imprint-
ed loci, CTCF functions as an enhancer blocker [62]. At the
paternal allele, DNA methylation prevents CTCF binding, and
allows enhancer activation of the Igf2 promoter. In contrast, at the
unmethylated maternal allele, CTCF binds to a cluster of sites and
prevents enhancer activation of the Igf2 promoter. Our findings
here and previously [55] suggest that CTCF may have enhancer
blocking activity at the sites surrounding OriP (e.g. the 59 site at
,6 kb and the 39 site at 10 kb on the EBV genome). These sites
are positioned to physically block OriP interactions with LMP1/2
and Cp, respectively. Interestingly, we found that CTCF binding
at the 59 site (,6 kb on EBV) is reduced in type I latency where
the sites have been partially subject to CpG DNA methylation.
Thus, latency type-specific DNA methylation patterns may
regulate CTCF binding at some regulatory regions. Conversely,
CTCF binding may prevent DNA methylation at other regulatory
elements. The region surrounding the Qp initiation site has been
shown to lack CpG methylation in all latency types [43]. The
CTCF site we identified may function to prevent the spread of
CpG methylation which is normally elevated in the regions
upstream of Qp (BFLF1 ORF) in both type I and type III latency.
Disruption of the CTCF site caused a significant increase in CpG
methylation immediately over the Qp initiation site (Fig. 7A).
Thus, an essential function of CTCF may be to prevent CpG
methylation at the Qp initiation site. This is consistent with the
observation that CpG methylation is never detected at Qp in any
EBV latency type [43].
Chromatin boundary factors, like CTCF, are thought to prevent
the spread of processive histone modifications [48]. Our data
suggests that CTCF has chromatin boundary activity at Qp that
prevents inactivating heterochromatin, like H3mK9 from invading
Qp. Elevation in H3mK9 at Qp was evident at 4 and 8 weeks post-
transfection in DCTCF, suggesting that this mark is the first to cross
into the Qp promoter region. At 16 weeks, mCpG is highly elevated
at Qp, thus following H3mK9 and more completely silencing Qp
transcription. Remarkably, the CTCF boundary functions in the
reciprocal direction since the loss of CTCF leads to elevated
transcription of Fp and BFLF1, along with a correspondingincrease
in histone H3mK4, and decrease in the normal H3mK9 and CpG
methylation.Itremainsunclearwhatdriveseachmodificationatthe
specific sites. Our data strongly suggests that H3mK9 precedes the
formation of mCpG, and that CTCF helps keep each modification
in its proper place. Precisely what sets the pattern on each side of
CTCF is not clear. CTCF may function in the recruitment of RNA
polymerase II to Qp, and this may help to establish the correct
orientation of the chromatin boundary at Qp. Loss of this boundary
function leads to the loss of Qp transcription and the inappropriate
regulation of other viral genes. CTCF also affected EBNA1 binding
to Qp in vivo (Fig. 4D), raising the possibility that EBNA1 may also
contribute to some of these changes in chromatin and transcription
at Qp. Furthermore, it is not known if CTCF or EBNA1 provide
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promoters, or if these are indirect effects of altering EBNA1 levels
in the 293 cell model of latency
DNA methylation, like histone modifications, can also spread
across chromosomal regions to alter gene expression programs
[63]. Epigenetic silencing due to promoter CpG methylation
commonly arises at sights that have been actively repressed by
histone deacetylation and K9 trimethylation. The mechanisms
that restrict the drift of CpG methylation have not been
completely elucidated. Our findings provide clear genetic evidence
that CTCF can prevent the encroachment of CpG methylation at
the Qp promoter of EBV. Our study shows that CpG methylation
arises only after multiple generations at a region that is initially
euchromatic and transcriptionally active. In the absence of CTCF,
transcription initiation favors an alternative upstream promoter,
Fp, which may prevent Qp utilization. Thus, CTCF may also
facilitate promoter selection perhaps through its reported ability to
interact with RNA polymerase II [64]. While the precise
mechanism through which CTCF directs promoter selection and
maintains chromatin boundaries remains to be discovered, our
findings clearly indicate that CTCF provides an essential function
in maintaining the epigenetic patterns at Qp. Our findings also
indicate that protection of Qp by CTCF is essential for EBV
genome stability during long-term latent infection. These findings
also provide a framework for understanding the role of CTCF at
other viral and cellular genes where protection from epigenetic
drift and transcription silencing is critical for stable gene
expression programs.
Materials and Methods
Cells
D98/HR1, HeLa and 293 cells were cultured in Dulbecco’s
modified Eagle’s medium supplemented with 10% fetal bovine
serum and antibiotics in a 5% CO2 incubator at 37uC. EBV
positive Mutu I, Mutu-lymphoblastoid cell lines (Mutu-LCL), Sav
I and Sav III cells were cultured in suspension in RPMI 1640
medium supplemented with 10% fetal bovine serum and
antibiotics in a 5% CO2 incubator at 37uC. Mutu-LCL were
established by primary infection of peripheral blood mononuclear
cells (PBMCs) with EBV virions derived from stimulated Mutu I
cells.
Bacmids, plasmids and recombinant proteins
EBV bacmid was a generous gift of Dr. H. –J. Delecluse [65].
Mutations in EBV bacmid were generated by recombineering
using the GalK marker gene insertion and negative selection
method for its substitution as described previously (http://
recombineering.ncifcrf.gov/) [56]. The GalK gene was recom-
bined into the Qp region at EBV coordinates 49927–50185. The
CTCF site at 50082 ggtcgctagatggcgcgggtgagg was mutated by
single substitutions to ggtTgTtaTatTTTAcgggtgagg. The
DEBNA1 binding site at 50142 gaaaag[gcgggatagcgtgcgctaccg-
gatggcgggtaatacatgct]atccttaca was mutated by deletion and
substitution with gaaag[tgcttgaaaaggcgcgg]atccttaca. Plasmid con-
taining the Qp region (49712–50250) was subcloned by PCR into
pBKSII using Asp718 and HinDIII sites. Recombinant human
CTCF protein was expressed as an N-terninal hexa-histidine
tagged fusion protein from a baculovirus expression virus in sf9
cells, as described previously[55].
Chromatin Immunoprecipitation (ChIP) assay
ChIP assay followed the protocol provided by Upstate
Biotechnology, Inc., with minor modifications as previously
described [54]. Additional modifications are as follows. DNAs
were sonicated to between 200- and 350-bp DNA fragments on a
Diagenode Bioruptor according to manufacturer’s protocol, and
real-time PCR was performed with SYBER green probe in an ABI
Prism 7900 using 1/100 to 1/2,500 of the ChIP DNA according
to manufacturer’s specified parameters. Primer sequences for the
EBV genome array are available upon request. Antibodies for H3
me2 K4, H3 me3 K9, CTCF, were purchased from Upstate
Biotechnology. Primary antibodies to EBNA1 (Advanced Biotech-
nologies, Inc.), CTCF (Millipore), GFP (Santa Cruz Biotecnology)
and PCNA (Santa Cruz Biotecnology) were used according to
manufacturer’s specifications
Electrophoretic mobility shift assay
EMSA assays with CTCF were described previously [55]. In a
20 ml reaction purified CTCF (,100 ng) was added to a reaction
mixture containing 0.5 mg poly(dI–dC), 5% glycerol, 0.1 mM
ZnSO4, and 10,000 cpm of
32P-labeled DNA probe (,0.1 ng).
Reaction mixtures were incubated for 30 min at 25uC, electro-
phoresed in a 5% nondenaturing, polyacrylamide gel at 110 V,
and visualized by PhosphorImager.
DNase I footprinting analysis
DNase I footprinting was performed as described previously
[66]. 59-end labeled DS probe was generated using 30 mCi of
[2
32P]dATP (6,000 Ci/mmol; Perkin-Elmer) and 2 U of Klenow
fragment (Roche) for 30 min at 25uC. Purified proteins were
incubated in a reaction mixture containing 1XPBS, 5 mM MgCl2,
0.1 mM ZnSO4, 1 mM dithiothreitol, 0.1% NP-40, 10% glycerol,
1 mg bovine serum albumin, 0.4 mg poly(dI–dC), and 10,000 cpm
of
32P-labeled probe. The protected probe was digested with
different dilutions of DNase I (Sigma) and purified by phenol-
chloroform extraction following proteinase K digestion. The DNA
samples were then electrophoresed on a 7% denaturing,
polyacrylamide sequencing gel at 33 mA and visualized by
PhosphorImager.
RNA extraction and RT-PCR
RNA was extract from 5610
6 cells using Qiagen RNA
extraction Kit according to manufacturer’s protocol (Qiagen).
After the extraction the RNA was incubated with 2 U DNAse I at
37uC for 30 minutes, following by the inactivation of the enzyme
at 65uC for 10 minutes. The RNA was quantified and 2 mgo f
RNA was reverse transcribed using Super Script II Reverse
Transcriptase from Invitrogen. 50 ng of cDNA was then analyzed
by real time or conventional PCR. Primer sequences used for real
time and conventional PCR are listened in tables 2 and 3 (Tables
S2 and S3).
EBV genome copy number quantification
For EBV genome quantification Namalwa titration was used,
assuming that Namalwa cell lines contain 2 copies of EBV genome
and each cell contain 6.6610
212 g of DNA. Namalwa cells and
EBV positive cells were lysed in SDS lysis buffer (20 mM Tris
pH 8, 4 mM EDTA, 20 mM NaCl, 1% SDS) following by
incubation with Proteinase K for 2 h at 50uC. The DNA was
extracted by phenol-chloroform extraction and precipitated by
ethanol. Titration of 6.6610
27–6.6610
212 g of Namalwa DNA
were used to obtain a calibration curve using primers for EBV
genome (48779 – 48834) and b-Actin. 6.6610
29 g of DNA from
EBV positive cells were then analyzed by real time PCR for EBV
genome copy quantification. Primer sequences used for real time
PCR were listed in Tables S2 and S3.
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10610
6 cells were resuspended in Lysis Buffer (20 mM Tris
pH 8, 4 mM EDTA, 20 mM NaCl, 1% SDS) plus 0.7 mg/ml
Proteinase K and incubated at 50uC overnight. The DNA was
extracted by twice phenol-chloroform extraction followed by
ethanol precipitation. The DNA was resuspended in 300 mlo fT E
buffer containing 20 mg/ml RNAse A and incubated at 37uC for
1 hr followed by DNA sonication to between 750 – 500 bp and
DNA purification by phenol-chloroform extraction and ethanol
precipitation. 8 mg of DNA were resuspended in Immunoprecip-
itation Buffer, IP buffer, [10 mM Na-Phosphate pH 7, 140 mM
NaCl, 0.05% Triton X-100, and Proteinase inhibitor cocktail
(Sigma)], denaturated at 95uC for 10 min and incubated with 5 mg
of 5-methylCytodine antibody (Abcam) or 5 mg mouse IgG
(Upstate), overnight at 4uC. The immunocomplexes were
precipited by adding 50 ml of Protein G Dynabeads (Invitrogen)
for 2 hr at 4uC. The beads were collected by a magnetic rack and
washed twice for 10 min with 1 ml of IP buffer. The DNA was
eluted by incubating the beads with 250 ml of Proteinase digestion
buffer (50 mM Tris pH 8, 10 mM EDTA, 0.5% SDS, 0.3 mg/ml
Proteinase K) at 50uC for 3 hr with shacking. The DNA was then
purified and then analyzed by real time PCR. Primer sequences
are listed in Table S4. 1 mg of genomic DNA was used as Input
material.
Quantitation of episomal DNA
Viral episomal DNA was extracted using the Hirt lysis method
[67] Briefly, Wt rescue and DCTCF 293 cells were pelleted by
centrifugation and then resuspended in 800 ml Hirt’s lysis buffer
(0.6% SDS, 10 mM EDTA, 10 mM Tris-HCl, pH 7.4) contain-
ing 500 mg Proteinase K. The samples were incubated at 37uC
for 1 h, followed by addition of 200 mlo f5 MN a C la n d
incubated at 37uC overnight. The samples were centrifuged at
14000 g for 20 minute and the supernatant was transferred in a
new tube. DNA was then purified by phenol/chloroform/
isoamyl alcohol extraction and ethanol precipitation. The DNA
was resuspended in 50 ml of TE buffer and analyzed by real
Time PCR by DDCt method, using mitochondrial DNA as
endogenous control and viral DNA extracted from Raji cell as a
standard.
Supporting Information
Table S1 CTCF binding site identified by ChIP assay
Found at: doi:10.1371/journal.ppat.1001048.s001 (0.04 MB
DOC)
Table S2 Primer sequences for Real Time PCR
Found at: doi:10.1371/journal.ppat.1001048.s002 (0.06 MB
DOC)
Table S3 Primer sequences for RT-PCR
Found at: doi:10.1371/journal.ppat.1001048.s003 (0.03 MB
DOC)
Table S4 Real time Primer sequences for Qp region
Found at: doi:10.1371/journal.ppat.1001048.s004 (0.04 MB
DOC)
Figure S1 Histone modifications and copy number of type I and
type III EBV latency. A) Histone modification analysis of Qp
region in different latency types. ChIP assay was performed with
Sav I (type I) or Sav III (type III) using antibodies for H3me2K4,
H3me3K9, CTCF and EBNA1 ChIP DNA was assayed by real
time PCR using primer sets for a region from 25.8 kb to +2.7 kb
of Qp. B) ChIP assay as in A but using IgG as control for non-
specific binding. C) EBV genome copy number in EBV positive
cells (Mut I, Mutu-LCL, Sav I, and Sav III) was quantified by real
time PCR.
Found at: doi:10.1371/journal.ppat.1001048.s005 (5.07 MB TIF)
Figure S2 EBNA2 RNA expression and promoter utilization in
different EBV cell lines. Real time PCR was used to validate the
pattern of gene expression program I or III in EBV positive cells
(Mutu I, Mutu-LCL, Sav I, and Sav III), by measuring Cp and Qp
promoter utilization and EBNA2 expression assays, as indicated.
Found at: doi:10.1371/journal.ppat.1001048.s006 (0.70 MB TIF)
Figure S3 Lytic replication was assayed in Rescue or DCTCF
293 cells pool. Virus reactivation was evaluated by real time PCR
measuring Zta mRNA expression in Rescue or DCTCF 293 cells
pool. Sodium butyrate (NaB) and phorbol ester (TPA) was used to
activate lytic replication from Wt rescue or DCTCF 293 cells pools
as a positive control.
Found at: doi:10.1371/journal.ppat.1001048.s007 (2.85 MB
TIF)
Figure S4 RNA expression and promoter utilization in GalK-
Qp mutated bacmids. A) Quantitative RT-PCR was used to
measure the abundance of EBNA2, EBNA3A and EBNA3C
mRNA relative to bacmid GFP for Wt rescue or GalK-Qp
bacmids in 293 cell pools. B) Same as in A, except mRNA for
EBNA1-transcripts were measured relative to GFP. C) RT-PCR
was measured for Wt rescue or GalK-Qp bacmids in 293 cell
pools, as well as for type I (Mutu I) or type III (Mutu-LCL)
controls. RNA was analyzed for initiation the junction specific
transcripts QUK (Qp initiation), C1C2W1W2 (Cp initiation),
W0W1W2 (Wp initiation), BFLF1 (lytic gene adjacent to Qp),
UK (EBNA1 mRNA in both type I and type III), and control
cellular GAPDH.
Found at: doi:10.1371/journal.ppat.1001048.s008 (4.37 MB TIF)
Figure S5 Change in Epigenetic patterns in Cp and Wp in
mutated bacmids. A) The epigenetic pattern of Cp and Wp in
Wt rescue and DCTCF bacmids in 293 cell pools was analyzed
by MeDIp assay (A), H3me2K4 (B) and H3me3K9 (C) ChIp
assay at 8 weeks (top panel) or 16 weeks (lower panel) after
transfection.
Found at: doi:10.1371/journal.ppat.1001048.s009 (4.54 MB
TIF)
Figure S6 Control ChIP for Figure 7 using non-specifc IgG is
shown for MeDIp (A) or ChIP (B) assays at the Qp, the Cp and the
Wp loci.
Found at: doi:10.1371/journal.ppat.1001048.s010 (3.04 MB TIF)
Figure S7 Normalization of RNA for RT-PCR. A) GFP mRNA
was normalized relative to cellular Actin at 8 and 16 weeks after
transfection into 293 cells for Wt rescue (black) and DCTCF (red)
bacmids. B) GFP mRNA was normalized relative to the DNA
copy number for each bacmid with same samples as shown in
panel A.
Found at: doi:10.1371/journal.ppat.1001048.s011 (0.14 MB TIF)
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